Lineage Cell Therapeutics vs Ocugen
LCTX and OCGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LCTX and OCGN compare
Ocugen is the larger company, worth 1.2 times as much as Lineage Cell Therapeutics ($281M against $231M).
Lineage Cell Therapeutics scores higher on the StockData Score (8 against 1 for Ocugen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LCTX | OCGN |
|---|---|---|
| Size and price | ||
| Market cap | $231M | $281M |
| Share price | $0.915 | $0.828 |
| Change, 1 year | −52.6% | −38.2% |
| Change, 5 years | −60.1% | −89.3% |
| Beta (5Y) | 0.96 | 1.65 |
| Employees | 77 | 116 |
| StockData Score | ||
| Total score | 8 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 3 (better) | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 21.3× | – |
| P/B | 3.4× | – |
| FCF yield | −11.4% (better) | −22.8% |
| Fair value | $0.620 | – |
| Margin of safety | −47.6% | – |
| Growth | ||
| Revenue growth (TTM) | 0.18% | – |
| Revenue growth, 5Y average | 51.5% | 152% (better) |
| Profitability | ||
| Operating margin | −280% | – |
| Net margin | 16.2% | – |
| FCF margin | −244% | – |
| Return on equity | 3.9% | – |
| Return on invested capital | −1395% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −6.8× |
| Current ratio | 5.96 (better) | 0.77 |
| Altman Z-score | −2.87 (better) | −6.98 |
| Piotroski F-score | 4 (better) | 0 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 46.1% | 42.8% |
| Held by insiders | 74.4% | 2.4% |
| Insider net buying, 12 months | $24.4K (better) | −$1.1M |
| Short interest, % of float | 37.7% | 32.5% |
Go deeper
- LCTX stock overview
- LCTX income statement
- LCTX valuation and score
- OCGN stock overview
- OCGN income statement
- OCGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.